Healthcare / Medical Instruments & SuppliesHKSE
$4.20
-0.01 (-0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.8M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
10.5x
↓EV/EBITDA
60.8x
↑ROE
10.1%
↑Gross Margin
67.8%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.7%
FCF CAGR
-61.5%
FCF margin
0.6%
FCF / Net income
0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $180.5M · net income $41.9M · FCF $1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $180.5M | $180.5M | $164.1M | $153.9M | $136.8M |
| Net Income | $41.9M | $41.9M | $39.7M | $45.1M | $18.5M |
| EBITDA | $53.5M | $53.5M | $47.9M | $54.0M | $27.1M |
| EPS | 0.05 | 0.05 | 0.05 | 0.05 | 0.03 |
| Gross Margin | 67.8% | 67.8% | 69.8% | 69.2% | 67.6% |
| Operating Margin | 22.1% | 22.1% | 21.4% | 25.6% | 17.6% |
| Net Margin | 23.2% | 23.2% | 24.2% | 29.3% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| Current Ratio | 10.54 | 10.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.1M | $1.1M | $1.8M | $15.6M | $20.1M |
| Returns | |||||
| ROE | 10.1% | 10.1% | 10.1% | 12.2% | 5.7% |
| Valuation | |||||
| P/E | 10.50 | 10.50 | 77.96 | 119.41 | 319.61 |
| EV/EBITDA | 60.83 | 60.83 | 59.55 | 95.11 | 224.88 |
| P/B | 8.39 | 8.39 | 7.88 | 14.61 | 19.62 |
| Growth & Yield | |||||
| Revenue Growth | 10.0% | 10.0% | 6.6% | 12.5% | — |
| EPS Growth | 5.6% | 5.6% | -11.1% | 112.2% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
94.3%
EPS terminal req.
$0.37
Spread vs growth
-88.7%
5Y implied EPS CAGR
54.8%
EPS terminal req.
$0.45
Spread vs growth
-49.1%
10Y implied EPS CAGR
30.5%
EPS terminal req.
$0.73
Spread vs growth
-24.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.8%
Start / end P/E
77.3x → 82.7x
EPS bridge
0.05 → 0.05
Residual
+0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.